Freenome (FRNM) Stock Price, News & Analysis

Company Overview

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology. The company’s products remain centered on research, clinical validation and regulatory development rather than a broad portfolio of established commercial diagnostic tests.

Key Stats

• Today's Range: $11.43 to $11.95
• 50-Day Range: N/A
• 52-Week Range: $9.97 to $14.26
• Volume: 775,419 shs
• Average Volume: 744,510 shs
• Market Capitalization: $94.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

Freenome Stock Analysis - MarketRank™

Freenome scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Freenome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Freenome has a consensus price target of $18.00, representing about 55.7% upside from its current price of $11.56.

Amount of Analyst Coverage

Freenome has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Freenome is -192.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for FRNM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Freenome does not currently pay a dividend.

Dividend Growth

Freenome does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Freenome has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Freenome this week, compared to 0 articles on an average week.

Search Interest

15 people have searched for FRNM on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Freenome insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.06% of the stock of Freenome is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Freenome has minimal institutional ownership at this time.

Company Calendar

• Today: 8/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FRNM
• CIK: 2017526
• Web: www.freenome.com
• Phone: (212) 284-2300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Freenome: $18.00
• High Price Target: $18.00
• Low Price Target: $18.00
• Potential Upside/Downside: +55.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $840 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2.70%
• Return on Assets: -0.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.20
• Quick Ratio: 0.20

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.09 per share
• Price / Cash Flow: 123.61
• Book Value: ($0.77) per share
• Price / Book: -15.01

Miscellaneous

• Outstanding Shares: 8,160,000
• Free Float: 6,358,000
• Market Cap: $94.33 million
• Optionable: N/A
• Beta: 0.35